Table 1.
Baseline demographic, disease, and treatment characteristics for intervention and control.
| Characteristic | Intervention (N = 15) | Control (N = 15) | p-Value |
|---|---|---|---|
| Age (mean [SD]) | 50.4 (18.1) | 48.4 (13.0) | 0.730 |
| Gender (male [%]) | 8 (53.3) | 7 (46.7) | 1.00 |
| BMI (mean [SD]) | 24.6 (3.3) | 26.1 (5.1) | 0.345 |
| Disease (%) | 0.145 | ||
| Leukemia | 9 (60.0) | 13 (86.7) | |
| Lymphoma | 1 (6.7) | 0 (0.0) | |
| Myelodysplastic syndrome | 5 (33.3) | 1 (6.7) | |
| Mitochondrial neurogastrointestinal encephalopathy syndrome | 0 (0.0) | 1 (6.7) | |
| Ethnicity (%) | 0.333 | ||
| East Asian | 2 (13.3) | 0 (0.0) | |
| West Asian | 2 (13.3) | 0 (0.0) | |
| South Asian | 0 (0.0) | 1 (6.7) | |
| White/Caucasian | 10 (66.7) | 10 (66.7) | |
| Black | 0 (0.0) | 1 (6.7) | |
| Jewish | 1 (6.7) | 1 (6.7) | |
| South East Asian | 0 (0.0) | 1 (6.7) | |
| West Indian | 0 (0.0) | 1 (6.7) | |
| Income (%) | 0.842 | ||
| <40,000 | 3 (21.4) | 2 (14.3) | |
| 40,000–80,000 | 3 (21.4) | 4 (28.6) | |
| >80,000 | 8 (57.1) | 8 (57.1) | |
| Marital status (%) | 0.909 | ||
| Single/never married | 4 (26.7) | 3 (20.0) | |
| Married/common law | 10 (66.7) | 11 (73.3) | |
| Divorced | 1 (6.7) | 1 (6.7) | |
| Education (%) | 0.74 | ||
| High school graduate | 1 (6.7) | 3 (20.0) | |
| Community college/trade school graduate | 1 (6.7) | 1 (6.7) | |
| University graduate | 10 (66.7) | 9 (60.0) | |
| Graduate university degree | 3 (20.0) | 2 (13.3) | |
| Work status (%) | 0.058 | ||
| Retired | 4 (26.7) | 0 (0.0) | |
| Unemployed | 2 (13.3) | 0 (0.0) | |
| Part-time | 1 (6.7) | 2 (13.3) | |
| Full-time | 7 (46.7) | 13 (86.7) | |
| Student | 1 (6.7) | 0 (0.0) | |
| Donor type † | 0.179 | ||
| Human leukocyte antigen matching related | 5 (45.5) | 8 (57.1) | |
| Human leukocyte antigen matching unrelated | 5 (45.5) | 3 (21.4) | |
| Haploidentical | 0 (0.0) | 3 (21.4) | |
| Missing | 1 (9.1) | 0 (0.0) | |
| HSCT conditioning protocol (%) | 0.18 | ||
| ECOG-2993 plus DASATINIB | 1 (6.7) | 0 (0.0) | |
| FBT(200) | 9 (60.0) | 14 (93.3) | |
| FBT(400) | 1 (6.7) | 0 (0.0) | |
| no HSCT * | 4 (26.7) | 1 (6.7) | |
| GVHD prophylaxis protocol (%) | 0.172 | ||
| ATG-CSA-MMF | 2 (13.3) | 0 (0.0) | |
| ATG-PTCY-CSA | 8 (53.3) | 13 (86.7) | |
| CSA-MTX | 1 (6.7) | 1 (6.7) | |
| no HSCT * | 4 (26.7) | 1 (6.7) | |
| Presence of acute GVHD (%) | 5 (33.3) | 8 (53.3) | 0.461 |
| Presence of chronic GVHD (%) | 3 (20.0) | 2 (13.3) | 1.0 |
| Use of steroids for GVHD symptom management (%) | 5 (33.3) | 3 (20.0) | 0.68 |
ATG: anti-thymocyte globulin; BMI: body mass index; CSA: cyclosporine A; MMF: mycophenolate mofetil; ECOG: Eastern Cooperative Oncology Group; FBT: fludarabine, busulfan, total body irradiation; GVHD: graft versus host disease; HSCT: hematopoietic stem cell transplant; MTX: methotrexate; PTCY: post transplant cyclophosphamide. * withdrawn from study due to change in eligibility status; † Excludes participants not eligible for transplant.